Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B
Zubiete-Franco, I.; Hu, Q.; Tonks, N. K.
Show abstract
CDKL5-deficiency disorder or CDD, which results in intellectual disability, speech and motor deficits, and seizures that can start as early as six weeks after birth, is caused by de novo mutations in the CDKL5 gene. In early 2022, the FDA approved Ganaxolone (Commercial name: Ztalmy) for treatment of seizures in CDD patients 2 years and older. Ganaxolone has been reported to act as a GABAA receptor agonist that helps reduce neuronal excitability; however, based on its chemical structure we hypothesized that ganaxolone may also act as a PTP1B inhibitor. We observed that ganaxalone was able to inhibit PTP1B activity both in an in vitro assay of enzyme activity and in different cell models, in a comparable way to known inhibitors of PTP1B, including MSI-1436, which has a similar chemical structure. Additionally, inhibition of PTP1B in differentiating SH-SY5Y cells increased TRKB/BDNF signaling. This effect was prominent in CDKL5-KO cells, where inhibition of PTP1B brought TRKB levels and BDNF signaling to levels similar to those of wild-type cells and the observed signaling changes also coincided with restoration of cellular morphology. Finally, loss of CDKL5 function resulted in increased levels of PTP1B. Our results suggest that, like in Rett syndrome, targeting PTP1B may be a beneficial therapeutic strategy for CDD.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Pharmacologically diverse antidepressant drugs disrupt the interaction of BDNF receptor TRKB and the endocytic adaptor AP-2 94%
- Contactin-1 is a critical neuronal cell surface receptor for perineuronal net structure 93%
- BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma 93%
Similar papers in this journal
- The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines. 93%
- Specific OCRL1 patient mutations differentially impact Lowe Syndrome cellular phenotypes 93%
- Spinocerebellar Ataxia Type 1 protein Ataxin-1 is signalled to DNA damage by Ataxia Telangiectasia Mutated kinase 92%
Similar papers in this journal
- Triac treatment prevents neurodevelopmental and locomotor impairments in thyroid hormone transporter Mct8/Oatp1c1 deficient mice 95%
- Differential Dynamics and Roles of FKBP51 Isoforms and Their Implications for Targeted Therapies 93%
- Kinase Suppressor of RAS 1 (KSR1) maintains the transformed phenotype of BRAFV600E mutant human melanoma cells 93%
Similar papers in this journal
Similar papers in this journal
- The nuclear receptor NR4A1 is regulated by SUMO modification to induce autophagic cell death 93%
- Identification of Hsp90 inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer 93%
- Dimeric prion protein ligand activates Adgrg6 but does not rescue myelinopathy of PrP-deficient mice 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.